{{Rsnum
|rsid=6477346
|Gene=PTPRD
|Chromosome=9
|position=8749291
|Orientation=plus
|GMAF=0.06198
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 100.0 | 0.0 | 0.0
| HCB | 91.2 | 8.8 | 0.0
| JPT | 96.5 | 3.5 | 0.0
| YRI | 66.7 | 31.3 | 2.0
| ASW | 68.4 | 28.1 | 3.5
| CHB | 91.2 | 8.8 | 0.0
| CHD | 96.3 | 3.7 | 0.0
| GIH | 99.0 | 1.0 | 0.0
| LWK | 65.1 | 32.1 | 2.8
| MEX | 94.8 | 5.2 | 0.0
| MKK | 71.2 | 24.4 | 4.5
| TSI | 95.1 | 4.9 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs6477346
|Name_s=
|Gene_s=PTPRD
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: G, MAF= 0.04, combined P value= 1.27E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470192
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6477346
|overall_frequency_n=9
|overall_frequency_d=128
|overall_frequency=0.0703125
|n_genomes=9
|n_genomes_annotated=0
|n_haplomes=10
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}